Type 1 diabetes
Poltreg S.A. focuses on presymptomatic type 1 diabetes in pediatric patients, with research centered on early immune intervention in stage 1 disease.
- Autoimmune diabetes
- Pediatric endocrinology
- Early-stage disease
The sponsor’s clinical interest includes immune-targeted approaches intended to address the onset of islet autoimmunity before clinical diabetes develops.
Cell therapy
Its research landscape includes regulatory T-cell–based therapy, with emphasis on CD4+CD25+CD127- regulatory lymphocytes as a therapeutic platform for immune modulation.
- Regulatory T cells
- Adoptive cell therapy
- Immune tolerance
This area reflects a therapeutic focus on restoring immune balance in autoimmune diabetes through cell-based intervention.
Immunotherapy
Poltreg S.A. also works in immune-directed therapy combining regulatory lymphocytes with anti-CD20 antibody treatment for pediatric autoimmune disease.
- Anti-CD20 therapy
- B-cell depletion
- Combination immunomodulation
The clinical interest lies in targeting both cellular and humoral components of the autoimmune process relevant to type 1 diabetes.
